Urophosphaulphol

Systemic antibiotic Urophosfabol is a drug based on phosphomycin, which refers to preparations of a broad spectrum of antimicrobial activity.

Indications of the urophosphatophile

Urophosfabol is prescribed for inflammatory infectious pathologies, if the causative agent of the disease is sensitive to the effects of the medication. Indication can be:

• infectious tissue lesions in diabetes mellitus, diseases of peripheral arteries, etc .;
• osteoarticular infectious diseases;
• infectious diseases of the respiratory system;
• abdominal infectious diseases;
• inflammatory processes in the pelvic organs;
• infectious lesions of the urinary system.

Release form

Urophosfabol has the appearance of a powdery mass of a whitish-yellowish hue, which is used to make an injection solution.

Active ingredient Urophosfabol is phosphomycin, and additional - succinic acid.

Powder Urophosfabol is packed in glass bottles of 20 ml, hermetically sealed with a rubber lid, covered with aluminum protection.

In one package is one bottle with a powdery mass.

Pharmacodynamics

Active ingredient Urophosfabol is an antibiotic that has a bactericidal effect on both gram-positive and gram-negative microbes. Urophosfabol is especially active in pseudomonas, protea, sheratia and highly resistant Staphylococcus strains and Escherichia.

Urophosfabol can accumulate in significant amounts in microbial cells, getting into them by means of active transportation.

Urophosfabol inhibits in the initial stages the biological synthesis of the peptide-adipose cell wall.

Pharmacokinetics

When carrying out intramuscular injection of Urophosphabol, the limiting plasma concentration concentrations are detected after 60 minutes and are estimated at 17.1 mg / liter and 28 mg / liter (with the appropriate administration of 500 mg and 1 g of the drug). When injected according to the 1 g schedule, a stable plasma concentration of 8 mg / liter can be maintained once every six hours.

The quality of the connection of the active ingredient Urophosfabol is relatively weak - 1% of the amount of medication delivered to the blood.

Low molecular weight of the active ingredient Urophosfabol contributes to the fact that it is perfectly distributed to organs and tissues. The quality bactericidal level of the antibiotic is found in the lungs, in the pleural and peritoneal fluids, in the biliary system, in the prostate, in the muscle and bone tissues, in the joints, in the vision organs, in the endocardium. Urofosfabol unhindered overcomes the blood-brain membrane.

The level of Urophosphabol in CSF is greatly increased in the presence of an inflammatory reaction in the membranes of the brain. The active ingredient has the ability to enter and accumulate in phagocytic cells, and also to pass through the placenta. In small quantities, the medication is determined in the composition of breast milk.

The half-life for an adult patient can be 90-120 minutes, and for a child 0.69-1.04 hours.

The primary way of removing the drug is through the kidneys, while the antibiotic in the active form is secreted with the urinary fluid. Removing the remainder of the drug with a caloric mass is not clinically important.

Urophosfabol can be removed from the serum by dialysis.

Dosing and administration

Urophosfabol is used in the form of intramuscular injections.

The standard amount of antibiotic for intramuscular injection is from 1 to 2 g three times a day. Children from 2.5 years of age are prescribed 0.5-1 g Urophosphabol thrice a day.

Patients with diagnosed renal failure, or with connected hemodialysis, it is necessary to adjust the scheme of administration Urophosphabol:

• when creatinine is cleared from 20 to 40 ml per minute, 2 to 4 g of Urophosphabol is injected once every 12 hours;
• when the creatinine is cleared from 10 to 20 ml per minute, 2 to 4 g of Urophosphabol is administered once a day;
• at a clearance of less than 10 ml per minute, 2 to 4 g of Urophosphabol is injected once every 2 days.

Patients who are on hemodialysis are prescribed 1-2 g Urophosphabol at the end of each dialysis session.

Intramuscular administration Urophosfabol can cause quite painful sensations.

To reduce the pain, the antibiotic solution is prepared as follows: 1 g Urophosphabolum is diluted in 2 ml of injection water, after which it is mixed with 2 ml of 2% lidocaine.

[2]

Use of the urophosphatophile during pregnancy

Purpose Urophosfabol during gestation is undesirable, and is only carried out in situations where the presumptive effect for a woman is more important than the likely danger to the future baby.

Since Urophosfabol is found in breast milk, its use in the lactation period is not recommended. If treatment is necessary, then during the course of antibiotic therapy, breast-feeding is suspended.

Contraindications

It is not recommended to prescribe the antibiotic Urophosfabol with an increased likelihood of developing allergies to the medication, as well as during pregnancy and in childhood to 2.5 years.

Relative contraindications are:

• severe liver damage;
• insufficient kidney function;
• old age;
• high blood pressure.

Side effects of the urophosphatophile

Urofosfabol is considered a low-toxic antibiotic: patients in most cases tolerate treatment well, and unfavorable symptoms are rarely noted.

In some cases, antibiotic therapy with Urophosphabol may be accompanied by:

• allergic reactions (rash, fever, cough or bronchospasm);
• disorders of hepatic function (laboratory - activation of alanine aminotransferase, alkaline phosphatase, bilirubin level);
• disorders of the digestive function (diarrhea, vomiting, abdominal pain, impaired appetite, inflammatory processes in the oral cavity);
• violations of the blood picture (a decrease in the level of eosinophils, leukocytes, less often - anemia and agranulocytosis);
• disorders of urinary function (increased urea levels, the presence of protein in the urine, a violation of the electrolyte balance);
• disorders in the central nervous system (dizziness, convulsions).

Some patients have a local reaction to the administration of Urophosfabol, which is expressed in pain and the appearance of a seal at the injection site.

In isolated cases, such phenomena as pain in the head, edema of the extremities, unpleasant sensation behind the sternum, an increase in heart activity were described.

[1]

Overdose

To date, there is no description of any cases of intoxication with Urophosfabol antibiotic.

Interactions with other drugs

A synergistic effect can be formed by the combination of Urophosfabol with medications such as penicillin and cephalosporin drugs, carbapenems, glycopeptides, fluoroquinolone and aminoglycoside agents. This property can be useful in antibiotic therapy of severe inflammatory pathologies, or infectious diseases provoked by resistant bacteria - pseudomonas, staphylococcus, enterococcus, enterobacteria, etc.

You can not mix in one injection Urophosfabol and Ampicillin, Kanamycin, Gentamicin, Rifampicin, Streptomycin.

[3]

Storage conditions

Keep Urophosphabol in a dark place - it is possible in a special cabinet, at a temperature not exceeding + 25 ° C. The storage location must be protected from access by children.

[4]

Shelf life

It is allowed to keep Urophosphabol for up to 2 years.